News VACCINEXPAR

Equities

VCNX

US9186403013

Delayed Nasdaq Other stock markets 08:23:06 01/05/2024 pm IST			5-day change	1st Jan Change
6.45 ^USD	+8.59%		+28.87%	-30.70%

12/04	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI
02/04	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

VACCINEXPAR : 12th Alzheimer’s & Parkinson’s Drug Development Summit Presentation	26/04	PU
Vaccinex, Inc. announced that it has received $1.75 million in funding	12/04	CI
Vaccinex Reports 2023 Financial Results and Provides Corporate Update	02/04	AQ
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding	29/03	CI
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	28/03	CI
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	27/03	AQ
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	27/03	CI
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding	27/03	CI
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024	05/03	CI
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	05/03	CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	22/02	MT
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	21/02	MT
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	21/02	CI
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology	21/02	AQ
Vaccinex, Inc. Announces Reverse Stock Split	15/02	AQ
Vaccinex Announces Pricing of $3.7 Million PIPE Financing	07/02	AQ
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding	07/02	CI
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule	04/12	AQ
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update	13/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News VACCINEXPAR

Equities

VCNX

US9186403013

Summary

Filters